Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21365729 | 0.99 | POLB (0.64) | KMT2AMEN1POLBPKMALDH1A1 | |
| SCHEMBL6166729 | 0.86 | POLB (0.66) | KMT2AMEN1POLBPKMALDH1A1 | |
| SCHEMBL6687183 | 0.77 | PTGDR2 (0.72) | KMT2AMEN1POLBALDH1A1HPGD | |
| SCHEMBL21365414 | 0.77 | POLB (0.69) | KMT2AMEN1POLBALDH1A1RAB9A | |
| SCHEMBL791659 | 0.77 | KMT2A (0.71) | KMT2AMEN1POLBALDH1A1LMNA | |
| SCHEMBL12169304 | 0.75 | KMT2A (0.69) | KMT2AMEN1POLBALDH1A1LMNA | |
| SCHEMBL17863711 | 0.75 | PTGDR2 (0.51) | KMT2AMEN1POLBALDH1A1LMNA | |
| SCHEMBL10627483 | 0.75 | PTGDR2 (0.51) | KMT2AMEN1POLBALDH1A1LMNA | |
| SCHEMBL6166972 | 0.75 | MEN1 (0.60) | KMT2AMEN1POLBALDH1A1GAA | |
| SCHEMBL7316803 | 0.75 | FKBP1A (0.67) | KMT2AMEN1POLBPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288534-B2 | Process for the preparation a ruthenium complex | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288534-B2 | Process for the preparation a ruthenium complex | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2276725-B1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | HOFFMANN LA ROCHE (CH) | 2012-07-04 | — | — | EP | disclosed |
| EP-2276725-B1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | HOFFMANN LA ROCHE (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-7939668-B2 | Ruthenium complexes as catalysts for metathesis reactions | ROCHE PALO ALTO LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939668-B2 | Ruthenium complexes as catalysts for metathesis reactions | ROCHE PALO ALTO LLC (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2276725-A1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | F. Hoffmann-La Roche AG (CH) | 2011-01-26 | — | — | EP | disclosed |
| WO-2010127964-A1 | PROCESS FOR THE PREPARATION OF RUTHENIUM METATHESIS COMPLEX CATALYSTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286403-A1 | PROCESS FOR THE PREPARATION A RUTHENIUM COMPLEX | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286403-A1 | PROCESS FOR THE PREPARATION A RUTHENIUM COMPLEX | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | ROCHE PALO ALTO LLC | 2009-11-05 | — | — | US | disclosed |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | ROCHE PALO ALTO LLC | 2009-11-05 | — | — | US | disclosed |
| WO-2009124853-A1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124853-A1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286403-A1 | PROCESS FOR THE PREPARATION A RUTHENIUM COMPLEX | CYP3A4, CYP3A5, CYP3A7 | KMT2A 4269/4885MEN1 193/4885POLB 443/4885 |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | HABP2, CYP3A7, ACE | KMT2A 4270/4885MEN1 2157/4885POLB 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.